Nuclear factor-erythroid 2-related factor 1 (NFE2L1, also known as NRF1) belongs to the CNC-bZIP family and is a master regulator of cellular adaptive responses to various stresses in many cells and tissues. Rosiglitazone (RGZ), a thiazolidinedione agonist of PPARγ, is widely used in the treatment of type 2 diabetes mellitus by stimulating genes which favor storage of triglycerides. Our previous studies demonstrated that loss of Nfe2l1 in adipocytes [Nfe2l1(f)-KO] resulted in diminished subcutaneous white adipose tissue (WAT) mass with adipocyte hypertrophy and severe adipose inflammation, which might be attributed, at least in part, to impaired lipolysis. However, the exact mechanism underlying this phenotype remains unclear. To further clarify the regulatory role of NFE2L1 in adipocyte lipid metabolism, we used protracted RGZ treatment to facilitate lipid accumulation in mice. In Nfe2l1flox/flox control mice, three weeks of RGZ treatment significantly downregulated mRNA levels of a group of inflammation-related genes in WAT. In contrast, the phenotype of Nfe2l1(f)-KO mice was aggravated showing increased transcript expression related to inflammation and pyroptosis in their shrunk WAT. These findings provide deeper insight into the mechanisms by which NFE2L1 regulates the expression of a set of lipolysis-related genes and controls WAT plasticity and global energy homeostasis.
Keywords: Adipocyte; Inflammation; Lipid metabolism; NFE2L1; RGZ.
Copyright © 2020 Elsevier Ltd. All rights reserved.